HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bonafide Women’s Health Acquires SAM-e Formulation With High Bioavailability

Executive Summary

Women’s health company acquired patent for SAM-e formulation MSI-195 after innovator's study showed it had nearly three times higher availability than a leading competitor.

You may also be interested in...



Research Bonafides, Detailing Gynecologists Included In Pharmavite's Third Women’s Health Line

“This acquisition, plus our existing women's health brands of Equelle and Uqora, positions us, the combined group, as the leader in women's health in nutraceuticals in the US,” says Pharmavite CEO Jeff Boutelle. Bonafide markets supplements for long-term, sustainable support for needs that compound with age, including hot flashes, vaginal dryness, vaginal microbiome and sexual satisfaction.

Pharmavite, GNC Launching SAM-e Dietary Supplement For Joints/Mood

Pharmavite and General Nutrition are introducing dietary supplements containing S-adenosylmethionine, a naturally occurring compound said to improve mood and help joints stay supple. BASF supplies the compound to Pharmavite and GNC; the raw material is produced in Italy.

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

AdvaMed’s new online clock documents the time since CMS promised to replace MCIT, a program guaranteeing coverage for FDA-cleared breakthrough devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel